Adolfo Fontenla

Adolfo Fontenla

Auto-generated profile, based on publicly available information

Adolfo Fontenla

Cardiology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain; Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in High Blood Pressure & Cardiovascular Prevention
Verified
Journal Article
Closed access
PDF file
AGArtemio García-Escobar
Artemio García-Escobar
RLRosa Lázaro-García
Rosa Lázaro-García
JGJavier Goicolea-Ruigómez
Javier Goicolea-Ruigómez
DGDavid González-Casal
David González-Casal
AFAdolfo Fontenla-Cerezuela
Adolfo Fontenla-Cerezuela
JCJosé Ángel Cabrera
José Ángel Cabrera

18 May 2023 in Heart Rhythm
Verified
Journal Article
Closed access
AFAdolfo Fontenla
Adolfo Fontenla
JTJuan Tamargo
Juan Tamargo
RSRicardo Salgado
Ricardo Salgado
MLMaría López-Gil
María López-Gil
EMElena Mejía
Elena Mejía
HBHector Bueno
Hector Bueno

28 May 2015 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
IAIgnasi Anguera
Ignasi Anguera
PDPaolo Dallaglio
Paolo Dallaglio
JMJose Martínez‐Ferrer
Jose Martínez‐Ferrer
ARAníbal Rodríguez
Aníbal Rodríguez
JAJavier Alzueta
Javier Alzueta
XSXavier Sabaté
Xavier Sabaté

11 December 2012 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
AFAdolfo Fontenla
Adolfo Fontenla
JGJosé A. García-Donaire
José A. García-Donaire
FHFelipe Hernández
Felipe Hernández
JSJulian Segura
Julian Segura
RSRicardo Salgado
Ricardo Salgado
FAFernando Arribas
Fernando Arribas

20 September 2013 in EP Europace
Verified
Journal Article
Open access
PDF file
MLMaríA LóPez-Gil
MaríA LóPez-Gil
RSRicardo Salgado
Ricardo Salgado
JMJose Luis Merino
Jose Luis Merino
TDTomáS Datino
TomáS Datino
JFJorge Figueroa
Jorge Figueroa
FAFernando Arribas
Fernando Arribas
A new remote catheter system (AMIGO™ Remote Catheter System) compatible with conventional ablation catheters is now commercially available but no data about its performance in clinical use during ablation have been reported. This study evaluates the feasibility, efficacy, and safety of cavo-tricuspid isthmus (CTI) ablation with this system in patients with typical atrial flutter (AFl). Sixty patients with typical AFl underwent CTI ablation using the new remote catheter navigation system with 8 mm tip or irrigated catheters in three centres following each centre's routine practice. The endpoint was stable bidirectional CTI block. CTI ablation was successful in 98% of patients. Ablation was completed manually in one patient. The overall procedure, fluoroscopy, and radiofrequency times (median ± standard deviation, range) were 123 ± 42 (50–250), 24 ± 13 (3–82), and 10 ± 8 (1.17–43.3) min, respectively. Three patients had vascular complications not requiring surgical intervention. There were no complications related to the remote catheter manipulation system. Cavo-tricuspid isthmus ablation for typical AFl can be safely and effectively performed with the AMIGO™. The learning curve seems to be short even for physicians with limited ablation experience.

13 June 2016 in Heart
Verified
Journal Article
Closed access
PDF file
JLJ M Lillo-Castellano
J M Lillo-Castellano
MMManuel Marina-Breysse
Manuel Marina-Breysse
AGAlfonso Gómez-Gallanti
Alfonso Gómez-Gallanti
JMJ B Martínez-Ferrer
J B Martínez-Ferrer
JAJavier Alzueta
Javier Alzueta
DFDavid Filgueiras-Rama
David Filgueiras-Rama
Objective A safety threshold for baseline rhythm R-wave amplitudes during follow-up of implantable cardioverter defibrillators (ICD) has not been established. We aimed to analyse the amplitude distribution and undersensing rate during spontaneous episodes of ventricular fibrillation (VF), and define a safety amplitude threshold for baseline R-waves. Methods Data were obtained from an observational multicentre registry conducted at 48 centres in Spain. Baseline R-wave amplitudes and VF events were prospectively registered by remote monitoring. Signal processing algorithms were used to compare amplitudes of baseline R-waves with VF R-waves. All undersensed R-waves after the blanking period (120 ms) were manually marked. Results We studied 2507 patients from August 2011 to September 2014, which yielded 229 VF episodes (cycle length 189.6±29.1 ms) from 83 patients that were suitable for R-wave comparisons (follow-up 2.7±2.6 years). The majority (77.6%) of VF R-waves (n=13953) showed lower amplitudes than the reference baseline R-wave. The decrease in VF amplitude was progressively attenuated among subgroups of baseline R-wave amplitude (≥17; ≥12 to <17; ≥7 to <12; ≥2.2 to <7 mV) from the highest to the lowest: median deviations −51.2% to +22.4%, respectively (p=0.027). There were no significant differences in undersensing rates of VF R-waves among subgroups. Both the normalised histogram distribution and the undersensing risk function obtained from the ≥2.2 to <7 mV subgroup enabled the prediction that baseline R-wave amplitudes ≤2.5 mV (interquartile range: 2.3–2.8 mV) may lead to ≥25% of undersensed VF R-waves. Conclusions Baseline R-wave amplitudes ≤2.5 mV during follow-up of patients with ICDs may lead to high risk of delayed detection of VF. Trial registration number NCT01561144; results.